HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Down 72.8% in September

HCW Biologics Inc. (NASDAQ:HCWB) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 9,274 shares, a drop of 72.8% from the August 31st total of 34,136 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 414,337 shares, the short-interest ratio is currently 0.0 days.

HCW Biologics Price Performance

NASDAQ:HCWB opened at $1.93 on Friday. The stock has a market capitalization of $3.55 million, a PE ratio of -0.07 and a beta of 2.37. The business’s 50-day simple moving average is $2.72 and its 200-day simple moving average is $4.36. HCW Biologics has a fifty-two week low of $1.50 and a fifty-two week high of $29.28.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing the consensus estimate of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic, low-grade inflammation, including cancer and age-related conditions. The company’s approach is designed to restore immune balance by reducing harmful inflammation while enhancing the body’s ability to generate an effective immune response.

HCW Biologics uses its proprietary Tissue-based Optimized Biologics Immunotherapy (TOBI™) platform to create engineered fusion-protein therapeutics.